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Mycotic aneurysms of the thoracic and abdominal
aorta have been estimated to occur in 1.3% of 2520
patients presenting to a single unit.1 Clinically, these
patients presented with painful, rapidly growing
aneurysms associated with fever, leukocytosis and
positive blood cultures. The traditional principles of
surgical treatment for mycotic aneurysms include the
debridement of all infected tissue, broad-spectrum
antibiotic cover, the use of muscle flaps to cover the
infected field, and either extra-anatomic or in situ
revascularisation with synthetic grafts or homografts.
In a series of 33 patients using extra-anatomic and in
situ revascularisation, the operative mortality was
36%.1 This and other papers suggest that traditional
open surgical repair is associated with significant
problems in patients with mycotic aneurysms.
The use of antibiotic impregnated or antibiotic coated
grafts seems to be a logical approach if a graft needs to
be placed in an infected tissue bed. Unfortunately, the
results of prophylactic antibiotic soaked grafts in three
randomised trials of grafts not used for infected
aneurysms failed to show any benefit.2 – 5 Rifampicin-
impregnated grafts showed a trend towards a ben-
eficial effect, but the difference was not statistically
significant in reducing post-operative infection. In
addition, the pathophysiology of the infected aorta
and the methods of prophylaxis may be more
complicated than first thought. For example, graft
infection may not be due to implantation of pathogenic
bacteria and may have more to do with the milieu of
an immunocompromised patient, poor tissues, and
inappropriate antibiotic therapy. Changing the surface
characteristics of the graft material to repel microbes is
one solution that has not yet been taken up by the graft
manufacturers presumably on economic grounds.
Other options include the production of silver coated
and Triclosan bonded grafts, but no convincing data
proving their benefit have been produced.6,7 Cur-
rently, the evidence does not support the use of
antibiotic coated grafts in open or endoluminal repair.
A mycotic aneurysm is fundamentally different to a
secondarily infected in situ graft and the results of one
cannot readily be applied to the other, although stent
grafts have been used in this clinical scenario.8
The endoluminal treatment of mycotic aneurysms
is controversial. However, the use of a stent to exclude
the infected portion of aorta, thereby allowing the
mycotic area to thrombose is similar in principle to an
open surgical bypass. The use of endovascular stents
to treat mycotic aneurysms has the potential benefit of
decreasing mortality and morbidity. This is due to
avoiding open repair, full heparinsation, significant
blood loss, aortic cross clamping, single-lung venti-
lation, prolonged distal ischaemia, and cardiopulmon-
ary bypass. The mortality of endoluminal procedures
is similar to, and in some series, better than traditional
open surgical repair in experienced hands.9 – 19
Reduction in mortality and morbidity should decrease
the costs of intensive care and length of hospital stay.
Returning patients to their activities of daily living
more quickly post-operatively can be very important
for their quality of life and their perception of a
proposed treatment plan. Stents may provide the
vascular surgeon with the option of performing open
repair at a later stage if further intervention becomes
necessary in a difficult clinical scenario. Potential
problems include the lack of debridement of infected
tissues which may result in infection of the stent graft,
with possible subsequent rupture of the aorta above or
below the device.
A review of the literature shows in-hospital
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mortality ranging from 0 to 40% for endoluminal
treatment of mycotic aneurysms.9 – 19 The stent graft
device may also be flushed with rifampicin when
being used for potentially infected aneurysms.12 Stents
are not the perfect answer and problems such as
rupture, migration, durability, gross oversizing or
undersizing, and operator inexperience have to be
addressed.20,21 The lack of debridement of the infected
bed of tissue together with the infected source seem to
be unique risks associated with endoluminal treat-
ment compared with traditional open repair. Compli-
cations that are similar to open repair include
paraplegia, stroke, and visceral ischaemia. The use of
cerebrospinal fluid drainage as an adjunct should be
considered.21 The development of branched stent
grafts may allow more mycotic aneurysms to be
treated in future, particularly those affecting the
origins of the visceral and renal vessels.
A multi-centre randomised clinical trial is required
to determine whether or not endoluminal treatment is
more effective than standard surgical care. However,
there are real difficulties in performing such a trial
given the relative rarity of the condition and the
numbers required to power such a study sufficiently.
National and international registries are an important
source of data for both endovascular and standard
open surgical repair. Since mycotic aneurysms of the
abdomen and thorax are fairly uncommon, it would
take a significant amount of time to accumulate useful
data. The randomised trial, nevertheless, remains the
best instrument to determine the optimum way to treat
this complex problem.
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